Clinical trials: ccRCC
Renal Cell Carcinoma, Kidney Cancer
Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody
This is a multicenter Phase III study to demonstrate the diagnostic utility of 124I-cG250 PET/CT pre-surgical imaging in patients with operable renal masses.
- Trial name
- NCT00606632
- Testing
- 124-Iodine-cG250 (124I-cG250), CT
- Where
- 14 sites in United States
- Volunteers
- 226 people
- Sponsor
- Heidelberg Pharma AG
Clear Cell Renal Cell Carcinoma
89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study
89Zr-TLX250 is under clinical development as a diagnostic agent targeting clear cell renal cell carcinoma.
- Trial name
- 89ZR-TLX250 (NCT03849118)
- Testing
- 89Zr-girentuximab
- Where
- 31 sites in United States, Australia and 6 more
- Volunteers
- 300 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Clear Cell Renal Cell Carcinoma
A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread
The purpose of this study is to evaluate the drug levels, efficacy, safety, and tolerability of subcutaneous nivolumab versus intravenous nivolumab in participants with previously treated clear cell renal cell carcinoma that is…
- Trial name
- CheckMate-67T (NCT04810078)
- Testing
- Nivolumab and rHuPH20, Nivolumab
- Where
- 89 sites in United States, Argentina and 15 more
- Volunteers
- 681 people
- Sponsor
- Bristol-Myers Squibb
Clear Cell Renal Cell Carcinoma
Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma
The study will evaluate the clinical activity of sitravatinib in combination with nivolumab in patients with locally-advanced clear cell renal cell carcinoma (ccRCC) in the neoadjuvant setting prior to nephrectomy.
- Trial name
- NCT03680521
- Testing
- Sitravatinib, Nivolumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Mirati Therapeutics Inc.
Solid Tumor, Clear Cell Renal Cell Carcinoma
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
This is a Phase 1b/2 study to determine the recommended phase 2 dose (RP2D), safety and tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor CB-839 with the poly adenosine diphosphate ribose…
- Conditions
- Solid Tumor, Clear Cell Renal Cell Carcinoma, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer
- Trial name
- NCT03875313
- Testing
- CB-839, Talazoparib
- Where
- 9 sites in United States
- Volunteers
- 33 people
- Sponsor
- Calithera Biosciences, Inc
Clear Cell Renal Cell Carcinoma (ccRCC), Melanoma
Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)
This study is an open-label Phase 1/2 evaluation of CB-839 in combination with nivolumab in participants with clear cell renal cell carcinoma, melanoma, and non-small cell lung cancer.
- Conditions
- Clear Cell Renal Cell Carcinoma (ccRCC), Melanoma, Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT02771626
- Testing
- CB-839, Nivolumab
- Where
- 17 sites in United States
- Volunteers
- 118 people
- Sponsor
- Calithera Biosciences, Inc
VHL Gene Mutation, VHL
MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003)
The primary objective of this study is to assess the overall response rate (ORR) of von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC) tumors in VHL participants treated with MK-3795.
- Conditions
- VHL Gene Mutation, VHL, VHL Syndrome, VHL Gene Inactivation
- Trial name
- NCT03108066
- Testing
- MK-3795
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)